Janssen will stop making injected, oral forms of antibiotic Levaquin

Johnson & Johnson's ($JNJ) Janssen Pharmaceuticals unit has notified the FDA that it has made a business decision to discontinue the production of the injected and oral forms of its antibiotic Levaquin. According to the FDA, no other explanation was given. The one-time substantial seller went off patent several years ago. The company has had to deal with thousands of lawsuits over claims that it didn't do enough to warn users about potential tendon injuries. Report | More

Suggested Articles

Fujifilm has completed the first manufacturing facility in Japan to make drug-delivering liposomes to use for cancer fighting drugs it is developing.

Three Samsung execs face up to two years in jail for their roles in destroying data and documents at under-fire affiliate Samsung BioLogics.

The FDA has slapped a U.S. drug repackager, saying in a warning letter that its storage processes and equipment cleaning are not up to expectations.